LXRX vs. XOMA, VSTM, VNDA, RIGL, RGLS, RZLT, OPK, INVA, MNKD, and IRWD
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include XOMA (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Rezolute (RZLT), OPKO Health (OPK), Innoviva (INVA), MannKind (MNKD), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
XOMA (NASDAQ:XOMA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
XOMA presently has a consensus price target of $74.00, indicating a potential upside of 191.80%. Lexicon Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 224.68%. Given XOMA's higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than XOMA.
In the previous week, XOMA had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for XOMA and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.20 beat XOMA's score of 0.12 indicating that XOMA is being referred to more favorably in the media.
95.9% of XOMA shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 7.2% of XOMA shares are owned by insiders. Comparatively, 6.8% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
XOMA has higher revenue and earnings than Lexicon Pharmaceuticals. XOMA is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
XOMA has a net margin of -886.91% compared to XOMA's net margin of -14,573.20%. Lexicon Pharmaceuticals' return on equity of -25.17% beat XOMA's return on equity.
XOMA has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
Lexicon Pharmaceuticals received 36 more outperform votes than XOMA when rated by MarketBeat users. However, 65.79% of users gave XOMA an outperform vote while only 64.66% of users gave Lexicon Pharmaceuticals an outperform vote.
Summary
XOMA beats Lexicon Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
